Hims & Hers Health, Inc.'s subscriber growth, Novo Nordisk partnership, and FDA pill approval could boost financials. Click ...

Novo Nordisk’s oral Wegovy pill for chronic weight loss is under FDA review. If approved, it would be the first oral GLP-1 ...

As weight loss medications, including Ozempic and WeGovy, have gained popularity across the U.S., they are not without side effects, some serious. According to a May 2024 CNN report, as many as 1 in 8 ...

CompanyOverview|NYSE:LLY] The world’s largest pharmaceutical stock, Eli Lilly and Company (NYSE: LLY), recently had its worst ...

Hims & Hers Health, Inc.'s Q1 results show 111% growth, yet shares fell 8%. Click for a look at the impact of drug access, ...

Shares of Eli Lilly (LLY -2.90%) sank after the drugmaker lowered its full-year profit outlook, and a potential headwind to ...

Another was a looming late-stage clinical trial of a closely watched pipeline drug that's loaded with potential. For a ...

Zepbound, Lilly’s obesity drug, has overtaken Novo’s equivalent, Wegovy, in the US and now commands over 50 per cent of the ...

Hims & Hers Health first-quarter revenue more than doubled as subscribers rose 38%, while its second-quarter sales outlook ...